Presentations & Publications
VRON-0200, a Therapeutic HBV Vaccine With an Intrinsic Checkpoint Inhibitor, Elicits Broad CD8+ T Cell Responses and Sustained Antiviral Declines in Preclinical Studies
Hasanpourghadi M, et al.
EASL, Abstract #OS-2478
Dr. Hildegund Ertl, Professor in the Vaccine & Immunotherapy Center at The Wistar Institute and the Scientific Founder of Virion Therapeutics, LLC, presented data on VRON-0200 chronic hepatitis B virus (HBV) program at the European Association for the Study of the Liver (EASL) – International Liver Congress (ILC) 2021. [12:30 mins]
This oral presented was identified for inclusion in Best of ILC.